Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti‐idiotype antibody

Background Anti‐CD38 antibodies such as daratumumab (DARA) are critical therapies for multiple myeloma and other diseases. Unfortunately, anti‐CD38 antibodies cause panreactivity in indirect antiglobulin tests (IATs), complicating blood compatibility testing. The anti‐CD38 interference is most often...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Transfusion (Philadelphia, Pa.) Pa.), 2022-08, Vol.62 (8), p.1511-1518
Hauptverfasser:	Aung, Fleur, Spencer, Jeff, Potter, David, Pham, Thuy‐Dung, Farooqui, Naheed, Platt, Kathryn R., Zayat, Raja, Oliveira, Melanie, Smeland‐Wagman, Robin, Petersen, Eric, Kaufman, Richard M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Alloantibodies Antibodies CD38 antigen Dithiothreitol Erythrocytes Immunotherapy Interference Monoclonal antibodies Multiple myeloma Neutralization Patients Reagents Targeted cancer therapy Transfusion
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!